Valuation: Cerevel Therapeutics Holdings, Inc.

Market Cap 8.19B 7.2B 6.63B 6.2B 11.63B 773B 11.84B 79.54B 30.81B 381B 30.76B 30.09B 1,324B P/E 2022
-13.6x
P/E 2023 -15.9x
Enterprise Value 7.5B 6.58B 6.07B 5.67B 10.64B 707B 10.83B 72.79B 28.19B 349B 28.15B 27.53B 1,212B EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
93.64%
Yield 2022 *
-
Yield 2023 -
3 years 19.59
Extreme 19.59
44.99
5 years 12.5
Extreme 12.5
46.16
10 years 9
Extreme 9
46.16
Manager TitleAgeSince
President 59 31/07/2024
Chief Tech/Sci/R&D Officer 57 30/04/2019
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 19/01/2021
Director/Board Member 59 31/07/2024
Date Insider Type Main position Quantity % Market Cap.
31/07/24
Bain Capital Private Equity LP
Issuer saleCompany 65,679,781 36.0492%
31/07/24Issuer sale

Director

93,932 0.0516%
31/07/24
Bain Capital Private Equity LP
Issuer saleCompany 65,679,781 36.0492%
Change 5-day change 1-year change 3-year change Capi.($)
+0.74%-.--%-.--%+38.94% 8.19B
+4.43%+2.49%+61.83%+115.25% 52.88B
+1.58%+19.37%+75.37%+85.18% 50.98B
-0.23%-0.98%-14.12%-16.00% 22.81B
+0.98%+9.05%-0.36%+423.40% 22.43B
+2.03%+7.40%+28.79%-12.32% 17.01B
+0.88%+5.78%+30.82%-34.26% 15.91B
+0.68%+2.54%+22.28%+168.03% 13.29B
+3.02%+12.74%+143.33%+308.04% 13.58B
+0.79%+1.59%+85.06%+116.18% 11.75B
Average +1.49%+5.31%+43.30%+119.24% 22.88B
Weighted average by Cap. +1.95%+6.31%+48.09%+117.61%

Financials

2022 2023
Net sales - -
Net income -352M -309M -284M -266M -499M -33.17B -508M -3.41B -1.32B -16.35B -1.32B -1.29B -56.82B -433M -380M -350M -328M -614M -40.84B -626M -4.2B -1.63B -20.13B -1.63B -1.59B -69.97B
Net Debt -523M -460M -423M -396M -743M -49.37B -756M -5.08B -1.97B -24.34B -1.96B -1.92B -84.58B -695M -611M -563M -526M -987M -65.62B -1.01B -6.75B -2.62B -32.35B -2.61B -2.55B -112B
Logo Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Employees
355
  1. Stock Market
  2. Stocks
  3. CERE Stock